Skip to content
Netazepide
Netazepide is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrophic gastritisD005757EFO_1000826K29.422
Barrett esophagusD001471EFO_0000280K22.722
Zollinger-ellison syndromeD015043E16.411
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Peptic esophagitisD004942EFO_100109544
DyspepsiaD004415EFO_0008533K3011
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNETAZEPIDE
INNnetazepide
Description
Netazepide is a protein pharmaceutical. It is currently being investigated in clinical studies.
Classification
Protein
Drug classcholecystokinin receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1
Identifiers
PDB
CAS-ID155488-25-8
RxCUI
ChEMBL IDCHEMBL324547
ChEBI ID
PubChem CID
DrugBank
UNII IDHOU4I0G29C (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 80 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details